Participants.
hepatitis
HEPATITIS
A total of 65 participants received at least one dose of GSK3389404 (The 64 participants included in this analysis were from mainland China (Baseline characteristicsALT, alanine aminotransferase; BMI, body mass index; CI, confidence interval; HBeAg, hepatitis B(e) antigen; HBsAg, hepatitis B surface antigen; NA, nucleos(t)ide analogue; PK, pharmacokinetics; ULN, upper limit of normal; yrs, years; wt, weight.A full PK profile consisted of plasma samples that were regularly collected for at least 8 h postdose.No participant had ALT >2× ULN at the baseline.No renal safety signal, including individual and mean changes from the baseline, was identified in participants receiving GSK3389404 during the study. There was no confirmed creatinine change from the baseline of >0.3 mg/dL. The mean glomerular filtration rate (mL/min/1.73 m